Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

"Back in the 1990s, multiple myeloma was a dreaded disease and patients had dismal outcomes," Vishwanath Sathyanarayanan, MD, DM, of Apollo Cancer Centers in Bangalore, India, said in an interview.

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

The first, MGUS, is considered the earliest precursor of multiple myeloma, before symptoms are present. This plasma cell ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...